1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2 Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nature reviews Cancer 2009; 9: 631-643.
3 Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007; 8: 229-239.
4 Lui KJ, Darrow WW, Rutherford GW, 3rd. A model-based estimate of the mean incubation period for AIDS in homosexual men. Science 1988; 240: 1333-1335.
5 Berry DA, Muss HB, Thor AD, Dressler L, Liu ET, Broadwater G et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18: 3471-3479.
6 Parisot JP, Hu XF, DeLuise M, Zalcberg JR. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. British journal of cancer 1999; 79: 693-700.
7 Ojo D, Wei F, Liu Y, Wang E, Zhang H, Lin X et al. Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion. Current medicinal chemistry 2015; 22: 2360-2374.
8 Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-2446.
9 Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nature reviews Clinical oncology 2015; 12: 573-583.
10 Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011; 29: 4160-4167.
11 Giacinti L, Claudio PP, Lopez M, Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006; 11: 1-8.
12 Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer research 2001; 61: 7025-7029.
13 Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol 2018; 29: 872-880.
14 Zhang X, Tanaka K, Yan J, Li J, Peng D, Jiang Y et al. Regulation of estrogen receptor alpha by histone methyltransferase SMYD2-mediated protein methylation. Proceedings of the National Academy of Sciences of the United States of America 2013; 110: 17284-17289.
15 Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Molecular endocrinology (Baltimore, Md) 2005; 19: 2671-2684.
16 Hatakeyama S. TRIM proteins and cancer. Nature reviews Cancer 2011; 11: 792-804.
17 Chu Y, Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene 2011; 30: 1108-1116.
18 El-Husseini AE, Fretier P, Vincent SR. Cloning and characterization of a gene (RNF22) encoding a novel brain expressed ring finger protein (BERP) that maps to human chromosome 11p15.5. Genomics 2001; 71: 363-367.
19 Huang XQ, Zhang XF, Xia JH, Chao J, Pan QZ, Zhao JJ et al. Tripartite motif-containing 3 (TRIM3) inhibits tumor growth and metastasis of liver cancer. Chin J Cancer 2017; 36: 77.
20 Liu Y, Raheja R, Yeh N, Ciznadija D, Pedraza AM, Ozawa T et al. TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1.). Oncogene 2014; 33: 308-315.
21 Lin JS, Lai EM. Protein-Protein Interactions: Co-Immunoprecipitation. Methods Mol Biol 2017; 1615: 211-219.
22 Li S, Wang M, Ao X, Chang AK, Yang C, Zhao F et al. CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the transcriptional activity of estrogen receptor-alpha. Oncogene 2013; 32: 4883-4891.
23 Traboulsi T, El Ezzy M, Dumeaux V, Audemard E, Mader S. Role of SUMOylation in differential ERalpha transcriptional repression by tamoxifen and fulvestrant in breast cancer cells. Oncogene 2019; 38: 1019-1037.
24 Kobayashi S, Shibata H, Yokota K, Suda N, Murai A, Kurihara I et al. FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr Res 2004; 30: 617-621.
25 Fu H, Yang H, Zhang X, Wang B, Mao J, Li X et al. Exosomal TRIM3 is a novel marker and therapy target for gastric cancer. Journal of experimental & clinical cancer research : CR 2018; 37: 162.
26 Raheja R, Liu Y, Hukkelhoven E, Yeh N, Koff A. The ability of TRIM3 to induce growth arrest depends on RING-dependent E3 ligase activity. The Biochemical journal 2014; 458: 537-545.
27 Zhu J, Wu G, Ke Z, Cao L, Tang M, Li Z et al. Targeting TRIM3 deletion-induced tumor-associated lymphangiogenesis prohibits lymphatic metastasis in esophageal squamous cell carcinoma. Oncogene 2019; 38: 2736-2749.
28 van Diepen MT, Spencer GE, van Minnen J, Gouwenberg Y, Bouwman J, Smit AB et al. The molluscan RING-finger protein L-TRIM is essential for neuronal outgrowth. Molecular and cellular neurosciences 2005; 29: 74-81.
29 Mukherjee S, Tucker-Burden C, Zhang C, Moberg K, Read R, Hadjipanayis C et al. Drosophila Brat and Human Ortholog TRIM3 Maintain Stem Cell Equilibrium and Suppress Brain Tumorigenesis by Attenuating Notch Nuclear Transport. Cancer research 2016; 76: 2443-2452.
30 Chen G, Kong J, Tucker-Burden C, Anand M, Rong Y, Rahman F et al. Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma. Cancer research 2014; 74: 4536-4548.
31 Piao MY, Cao HL, He NN, Xu MQ, Dong WX, Wang WQ et al. Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development. Scand J Gastroenterol 2016; 51: 572-582.
32 Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clinical cancer research : an official journal of the American Association for Cancer Research 2003; 9: 1980-1989.
33 Gao A, Sun T, Ma G, Cao J, Hu Q, Chen L et al. LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERalpha pathway. Nature communications 2018; 9: 4180.
34 He H, Sinha I, Fan R, Haldosen LA, Yan F, Zhao C et al. c-Jun/AP-1 overexpression reprograms ERalpha signaling related to tamoxifen response in ERalpha-positive breast cancer. Oncogene 2018; 37: 2586-2600.
35 Karamouzis MV, Konstantinopoulos PA, Badra FA, Papavassiliou AG. SUMO and estrogen receptors in breast cancer. Breast Cancer Res Treat 2008; 107: 195-210.
36 Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW et al. P300 transcriptional repression is mediated by SUMO modification. Molecular cell 2003; 11: 1043-1054.
37 Kuo HY, Chang CC, Jeng JC, Hu HM, Lin DY, Maul GG et al. SUMO modification negatively modulates the transcriptional activity of CREB-binding protein via the recruitment of Daxx. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 16973-16978.
38 Yu EJ, Kim SH, Kim MJ, Seo WY, Song KA, Kang MS et al. SUMOylation of ZFP282 potentiates its positive effect on estrogen signaling in breast tumorigenesis. Oncogene 2013; 32: 4160-4168.
39 Mo YY, Yu Y, Theodosiou E, Ee PL, Beck WT. A role for Ubc9 in tumorigenesis. Oncogene 2005; 24: 2677-2683.